Cardiol Therapeutics Inc.
CRDL
Rank in Stocks
#18645
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company,... Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
Share Price
$1.03
Last synced: 2026-11-09
Market Cap
$126.46M
Change (1 day)
3.52%
Change (1 year)
-0.96%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cardiol Therapeutics Inc. (CRDL)
Category
Healthcare
Operating Margin for Cardiol Therapeutics Inc. (CRDL)
Operating Margin as of November 2026 TTM: 0.00%
According to Cardiol Therapeutics Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Cardiol Therapeutics Inc. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | -57,736.32% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | - |
DE
|
|
| 19.68% | - |
DE
|
|
| 13.26% | - |
JP
|
|
| 17.08% | - |
CH
|
|
| 14.92% | - |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Cardiol Therapeutics Inc.'s operating margin
What was Cardiol Therapeutics Inc.'s operating margin in 2025?
In 2025, Cardiol Therapeutics Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Cardiol Therapeutics Inc.'s operating margin changed since 2020?
From 2020 to 2025, Cardiol Therapeutics Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2021 (-57,736.32%).
How does Cardiol Therapeutics Inc.'s operating margin compare with similar companies?
Cardiol Therapeutics Inc.'s operating margin (0.00%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.